New Combo Therapy May Prevent TB, Save Lives in People
WEDNESDAY, July 6 (HealthDay News) -- Simpler and shorter
treatment with antibiotic drugs could help prevent full-blown
tuberculosis in millions of people worldwide infected with the
bacterium that causes TB, especially those also infected with HIV,
TB, or tuberculosis, is the leading cause of death among people
co-infected with HIV, the virus that causes AIDS. About half a
million people with both infections die worldwide every year.
The new study by an international team of scientists included
1,148 South African men and women infected with the TB bacterium
and HIV, who were followed for up to six years to see whose TB
infections stayed dormant.
It found that the most streamlined combination treatment -- a
high dose of 900 milligrams each of the newer antibiotic
rifapentine (Priftin) and the traditional anti-TB antibiotic
isoniazid once weekly for three months -- worked as well or better
than the current gold standard of care of 300 mg of isoniazid taken
daily for six months or longer.
Of the study volunteers, about 3.1 percent on the shorter drug
regimen developed active TB or died each year, compared to 3.6
among those on the standard daily regimen. Without treatment,
researchers estimated that the mortality rate would have
Compliance with the drug regimen was also 95 percent for the
shorter regimen, compared to 60 percent that other studies showed
for the standard regimen.
The study appears online July 7 in the
New England Journal of Medicine.
"This new, simpler treatment regimen with rifapentine and isoniazid is highly effective and could transform therapy for latent tuberculosis in both those co-infected with HIV and those not," senior author Dr. Richard Chaisson, a professor of infectious diseases at the Johns Hopkins University School of Medicine and founding director of its Center for Tuberculosis Research, said in a Hopkins news release.
"New treatment options are urgently needed to help control TB globally, and simpler regimens will substantially increase the number of people receiving therapy," Chaisson added.
He noted that fewer than 1 percent of those infected and most
likely to develop full-blown TB receive drug treatment because of
factors such as inconvenience, drug side effects and difficulty
finding nearby health clinics.
The U.S. National Institute of Allergy and Infectious has more
Copyright © 2011
. All rights reserved.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.